{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:11Z","timestamp":1788865991350,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12659-0","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:42:14Z","timestamp":1788860534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protease inhibition: breaking the barriers of chemoresistance in cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Gino A.","family":"Kurian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"12659_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","volume":"16","author":"A Zafar","year":"2025","unstructured":"Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A (2025) Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol 16:607","journal-title":"Discov Oncol"},{"key":"12659_CR2","first-page":"1","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY (2024) Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther 9:1","journal-title":"Signal Transduct Target Ther"},{"key":"12659_CR3","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.3390\/biomedicines10112988","volume":"10","author":"EJ Kilmister","year":"2022","unstructured":"Kilmister EJ, Koh SP, Weth FR, Gray C, Tan ST (2022) Cancer metastasis and treatment resistance: mechanistic insights and therapeutic targeting of cancer stem cells and the tumor microenvironment. Biomedicines 10:2988","journal-title":"Biomedicines"},{"key":"12659_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/DDDT.S285852","volume":"15","author":"M Rudzi\u0144ska","year":"2021","unstructured":"Rudzi\u0144ska M, Daglioglu C, Savvateeva LV, Kaci FN, Antoine R, Zamyatnin AA (2021) Current status and perspectives of protease inhibitors and their combination with nanosized drug delivery systems for targeted cancer therapy. Drug Des Devel Ther 15:9","journal-title":"Drug Des Devel Ther"},{"key":"12659_CR5","doi-asserted-by":"publisher","first-page":"6805","DOI":"10.3390\/ijms21186805","volume":"21","author":"KC Park","year":"2020","unstructured":"Park KC, Dharmasivam M, Richardson DR (2020) The role of extracellular proteases in tumor progression and the development of innovative metal ion chelators that inhibit their activity. Int J Mol Sci 21:6805","journal-title":"Int J Mol Sci"},{"key":"12659_CR6","doi-asserted-by":"publisher","first-page":"128658","DOI":"10.1016\/j.ijbiomac.2023.128658","volume":"257","author":"F Guo","year":"2024","unstructured":"Guo F, Du Y, Wang Y, Wang M, Wang L, Yu N, Luo S, Wu F, Yang G (2024) Targeted drug delivery systems for matrix metalloproteinase-responsive nanoparticles in tumor cells: a review. Int J Biol Macromol 257:128658","journal-title":"Int J Biol Macromol"},{"key":"12659_CR7","doi-asserted-by":"publisher","first-page":"119532","DOI":"10.1016\/j.bbamcr.2023.119532","volume":"1870","author":"T Hua","year":"2023","unstructured":"Hua T, Robitaille M, Roberts-Thomson SJ, Monteith GR (2023) The intersection between cysteine proteases, Ca\u00b2\u207a signalling and cancer cell apoptosis. Biochim Biophys Acta Mol Cell Res 1870:119532","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"12659_CR8","doi-asserted-by":"crossref","unstructured":"Ansari M, Kurian GA (2020) Mechanism of hydrogen sulfide preconditioning\u2013associated protection against ischemia\u2013reperfusion injury differs in diabetic heart. Cardiovasc Toxicol","DOI":"10.1007\/s12012-019-09542-9"},{"key":"12659_CR9","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.3390\/ijms21124526","volume":"21","author":"G Barillari","year":"2020","unstructured":"Barillari G (2020) The impact of matrix metalloproteinase-9 on the sequential steps of the metastatic process. Int J Mol Sci 21:4526","journal-title":"Int J Mol Sci"},{"key":"12659_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13046-023-02805-y","volume":"42","author":"H Gao","year":"2023","unstructured":"Gao H, Yin J, Ji C, Yu X, Xue J, Guan X (2023) Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application. J Exp Clin Cancer Res 42:225","journal-title":"J Exp Clin Cancer Res"},{"key":"12659_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X (2022) The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol 15:97","journal-title":"J Hematol Oncol"},{"key":"12659_CR12","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/cancers16132478","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS (2024) Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers 16:2478","journal-title":"Cancers"},{"key":"12659_CR13","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/biomedicines9101353","volume":"9","author":"WH Talib","year":"2021","unstructured":"Talib WH, Alsayed AR, Barakat M, Abu-Taha MI, Mahmod AI (2021) Targeting drug chemo-resistance in cancer using natural products. Biomedicines 9:1353","journal-title":"Biomedicines"},{"key":"12659_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tips.2020.01.001","volume":"41","author":"N Kozlova","year":"2020","unstructured":"Kozlova N, Grossman JE, Iwanicki MP, Muranen T (2020) The interplay of the extracellular matrix and stromal cells as a drug target in stroma-rich cancers. Trends Pharmacol Sci 41:183","journal-title":"Trends Pharmacol Sci"},{"key":"12659_CR15","doi-asserted-by":"publisher","first-page":"1486783","DOI":"10.3389\/fphar.2024.1486783","volume":"15","author":"XY Lu","year":"2024","unstructured":"Lu XY, Jin H (2024) MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters. Front Pharmacol 15:1486783","journal-title":"Front Pharmacol"},{"key":"12659_CR16","doi-asserted-by":"publisher","first-page":"8378","DOI":"10.1038\/s41598-025-92805-z","volume":"15","author":"M Bozdaganyan","year":"2025","unstructured":"Bozdaganyan M, Fedorov V, Kholina E, Kovalenko I, Gudimchuk N, Orekhov P (2025) Exploring tubulin-paclitaxel binding modes through extensive molecular dynamics simulations. Sci Rep 15:8378","journal-title":"Sci Rep"},{"key":"12659_CR17","doi-asserted-by":"publisher","first-page":"e23544","DOI":"10.1002\/jbt.23497","volume":"37","author":"CH Chiu","year":"2023","unstructured":"Chiu CH, Lin YJ, Ramesh S, Kuo WW, Chen MC, Kuo CH (2023) Gemcitabine resistance in non-small cell lung cancer is mediated through activation of the PI3K\/AKT\/NF-\u03baB pathway and suppression of ERK signaling by reactive oxygen species. J Biochem Mol Toxicol 37:e23544","journal-title":"J Biochem Mol Toxicol"},{"key":"12659_CR18","doi-asserted-by":"publisher","first-page":"150969","DOI":"10.1016\/j.bbrc.2024.150969","volume":"624","author":"M Sahadevan","year":"2024","unstructured":"Sahadevan M, Subramanian K, Sundaram M (2024) Quantum mechanical approaches and molecular docking studies of platinum based anticancer drugs satraplatin and picoplatin structures. Biochem Biophys Res Commun 624:150969","journal-title":"Biochem Biophys Res Commun"},{"key":"12659_CR19","doi-asserted-by":"publisher","first-page":"739145","DOI":"10.3389\/fonc.2021.739145","volume":"11","author":"J Li","year":"2021","unstructured":"Li J, Zhou W, Mao Q, Gao D, Xiong L, Hu X, Xu X (2021) HMGB1 promotes resistance to doxorubicin in human hepatocellular carcinoma cells by inducing autophagy via the AMPK\/mTOR signaling pathway. Front Oncol 11:739145","journal-title":"Front Oncol"},{"key":"12659_CR20","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.3390\/ijms25063124","volume":"25","author":"JH Im","year":"2024","unstructured":"Im JH, Lee KY, Seo Y, Rhim J, Dho YS, Yoo BC, Park JB, Shin SH, Yoo H, Kim JH, Gwak HS (2024) Extracellular vesicles from cerebrospinal fluid of leptomeningeal metastasis patients deliver miR-21 and induce methotrexate resistance in lung cancer cells. Int J Mol Sci 25:3124","journal-title":"Int J Mol Sci"},{"key":"12659_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13046-023-02876-x","volume":"42","author":"K Wimmer","year":"2023","unstructured":"Wimmer K, Sachet M, Ramos C, Frantal S, Birnleitner H, Brostjan C, Exner R, Filipits M, Bago-Horvath Z, Rudas M, Bartsch R, Gnant M, Singer CF, Balic M, Egle D, Oehler R, Fitzal F (2023) Differential immunomodulatory effects of epirubicin\/cyclophosphamide and docetaxel in breast cancer patients. J Exp Clin Cancer Res 42:300","journal-title":"J Exp Clin Cancer Res"},{"key":"12659_CR22","doi-asserted-by":"publisher","first-page":"21456","DOI":"10.1038\/s41598-023-49464-9","volume":"13","author":"J Raut","year":"2023","unstructured":"Raut J, Sarkar O, Das T, Mandal SM, Chattopadhyay A, Sahoo P (2023) Efficient delivery of methotrexate to MDA-MB-231 breast cancer cells by a pH-responsive ZnO nanocarrier. Sci Rep 13:21456","journal-title":"Sci Rep"},{"key":"12659_CR23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41419-023-05972-0","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Wang Y, Zhang Y, Ye F, Luo D, Li Y (2023) HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-\u03baB signaling pathway in breast cancer. Cell Death Dis 14:434","journal-title":"Cell Death Dis"},{"key":"12659_CR24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41417-023-00643-w","volume":"30","author":"KB Piotrowski","year":"2023","unstructured":"Piotrowski KB, Blasco LP, Sams\u00f8e-Petersen J, Eefsen RL, Illemann M, Oria VO, Campos KIA, Lopresti AM, Albrechtsen R, S\u00f8rensen CS, Sun XF, Kveiborg M, Gnosa S (2023) ADAM12 expression is upregulated in cancer cells upon radiation and constitutes a prognostic factor in rectal cancer patients following radiotherapy. Cancer Gene Ther 30:1369","journal-title":"Cancer Gene Ther"},{"key":"12659_CR25","doi-asserted-by":"publisher","first-page":"19807","DOI":"10.1002\/cam4.6552","volume":"12","author":"H Xu","year":"2023","unstructured":"Xu H, Li L, Dong B, Lu J, Zhou K, Yin X (2023) TRAF6 promotes chemoresistance to paclitaxel of triple-negative breast cancer via regulating PKM2-mediated glycolysis. Cancer Med 12:19807","journal-title":"Cancer Med"},{"key":"12659_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, Tian X, Guan X, Cen X, Zhao Y (2024) Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther 9:132","journal-title":"Signal Transduct Target Ther"},{"key":"12659_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cells14100713","volume":"14","author":"SK Hasan","year":"2025","unstructured":"Hasan SK, Jayakumar S, Espina Barroso E, Jha A, Catalano G, Sandur SK (2025) Molecular targets of oxidative stress: focus on nuclear factor erythroid 2\u2013related factor 2 function in leukemia and other cancers. Cells 14:713","journal-title":"Cells"},{"key":"12659_CR28","doi-asserted-by":"crossref","unstructured":"Kurian GA, Rajagopal R, Vedantham S, Mohanraj R (2016) The role of oxidative stress in myocardial tissue injury & remodeling: revisited. Oxid Med Cell Longev","DOI":"10.1155\/2016\/1656450"},{"key":"12659_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.advms.2023.09.013","volume":"68","author":"K Wojtowicz","year":"2023","unstructured":"Wojtowicz K, \u015awierczewska M, Nowicki M, Januchowski R (2023) The TGFBI gene and protein expression in topotecan resistant ovarian cancer cell lines. Adv Med Sci 68:379","journal-title":"Adv Med Sci"},{"key":"12659_CR30","doi-asserted-by":"publisher","first-page":"e33687","DOI":"10.1016\/j.heliyon.2024.e33687","volume":"10","author":"G Ou","year":"2024","unstructured":"Ou G, Tian Z, Su M, Yu M, Gong J, Chen Y (2024) Identification of gemcitabine resistance-related AHNAK2 gene associated with prognosis and immune infiltration in pancreatic cancer. Heliyon 10:e33687","journal-title":"Heliyon"},{"key":"12659_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijms23095176","volume":"23","author":"BP Rickard","year":"2022","unstructured":"Rickard BP, Tan X, Fenton SE, Rizvi I (2022) Select per- and polyfluoroalkyl substances (PFAS) induce resistance to carboplatin in ovarian cancer cell lines. Int J Mol Sci 23:9","journal-title":"Int J Mol Sci"},{"key":"12659_CR32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s12276-022-00809-w","volume":"54","author":"H Ma","year":"2022","unstructured":"Ma H, Qi G, Han F, Peng J, Yuan C, Kong B (2022) PBK drives PARP inhibitor resistance through the TRIM37\/NF\u03baB axis in ovarian cancer. Exp Mol Med 54:999","journal-title":"Exp Mol Med"},{"key":"12659_CR33","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1111\/cas.14532","volume":"111","author":"S Blondy","year":"2020","unstructured":"Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N (2020) 5-fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci 111:3142","journal-title":"Cancer Sci"},{"key":"12659_CR34","doi-asserted-by":"publisher","first-page":"6887","DOI":"10.1007\/s00018-021-03901-y","volume":"78","author":"S Kukal","year":"2021","unstructured":"Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P (2021) Multidrug efflux transporter ABCG2: expression and regulation. Cell Mol Life Sci 78:6887","journal-title":"Cell Mol Life Sci"},{"key":"12659_CR35","first-page":"1025","volume":"56","author":"Q Ma","year":"2020","unstructured":"Ma Q, Wu H, Xiao Y, Liang Z, Liu T (2020) Upregulation of exosomal microRNA-21 in pancreatic stellate cells promotes pancreatic cancer cell migration and enhances Ras\/ERK pathway activity. Int J Oncol 56:1025","journal-title":"Int J Oncol"},{"key":"12659_CR36","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41419-022-05103-1","volume":"13","author":"C Chen","year":"2022","unstructured":"Chen C, Zhao S, Zhao X, Cao L, Karnad A, Kumar AP, Freeman JW (2022) Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching. Cell Death Dis 13:682","journal-title":"Cell Death Dis"},{"key":"12659_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fphar.2020.00343","volume":"11","author":"J Zhou","year":"2020","unstructured":"Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S (2020) The drug-resistance mechanisms of five platinum-based antitumor agents. Front Pharmacol 11:343","journal-title":"Front Pharmacol"},{"key":"12659_CR38","doi-asserted-by":"publisher","first-page":"111981","DOI":"10.1016\/j.yexcr.2020.111981","volume":"390","author":"S Luo","year":"2020","unstructured":"Luo S, Shao L, Chen Z, Hu D, Jiang L, Tang W (2020) NPRL2 promotes docetaxel chemoresistance in castration-resistant prostate cancer cells by regulating autophagy through the mTOR pathway. Exp Cell Res 390:111981","journal-title":"Exp Cell Res"},{"key":"12659_CR39","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1080\/03007995.2024.2366430","volume":"40","author":"K Bir Y\u00fccel","year":"2024","unstructured":"Bir Y\u00fccel K, U\u011frakl\u0131 M, Sekmek S, Y\u0131ld\u0131r\u0131m N, G\u00fcrler F, Yaz\u0131c\u0131 O, \u00d6zet A, Bal \u00d6, Araz M, Arta\u00e7 M, \u00d6zdemir N (2024) Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group study. Curr Med Res Opin 40:1137","journal-title":"Curr Med Res Opin"},{"key":"12659_CR40","doi-asserted-by":"publisher","first-page":"10791","DOI":"10.1038\/s41598-021-89931-9","volume":"11","author":"W Yin","year":"2021","unstructured":"Yin W, Xiang D, Wang T, Zhang Y, Pham CV, Zhou S, Jiang G, Hou Y, Zhu Y, Han Y, Qiao L, Tran PH, Duan W (2021) The inhibition of ABCB1\/MDR1 or ABCG2\/BCRP enables doxorubicin to eliminate liver cancer stem cells. Sci Rep 11:10791","journal-title":"Sci Rep"},{"key":"12659_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3892\/ijo.2020.5054","volume":"57","author":"HY Wang","year":"2020","unstructured":"Wang HY, Wang YP, Zeng X, Zheng Y, Guo QH, Ji R (2020) Circular RNA is a popular molecule in tumors of the digestive system (review). Int J Oncol 57:21","journal-title":"Int J Oncol"},{"key":"12659_CR42","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1038\/s41598-025-90532-z","volume":"15","author":"C Zhong","year":"2025","unstructured":"Zhong C, Wang S, Jiang WJ, Li Z, Wang X, Fan S, Huang J, Wu HJ, Sheng R, Fei T (2025) Chemoresistance mechanisms to 5-fluorouracil and reversal strategies in lung and breast cancer. Sci Rep 15:6074","journal-title":"Sci Rep"},{"key":"12659_CR43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12032-025-02830-1","volume":"42","author":"F Rizwani","year":"2025","unstructured":"Rizwani F, Patil P, Jain K (2025) Unlocking glioblastoma: breakthroughs in molecular mechanisms and next-generation therapies. Med Oncol 42:276","journal-title":"Med Oncol"},{"key":"12659_CR44","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/neuonc\/noae059","volume":"26","author":"S Budhiraja","year":"2024","unstructured":"Budhiraja S, McManus G, Baisiwala S, Perrault EN, Cho S (2024) Saathoff M, ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma. Neuro Oncol 26:1421","journal-title":"Neuro Oncol"},{"key":"12659_CR45","doi-asserted-by":"publisher","first-page":"1331687","DOI":"10.3389\/fphar.2023.1331687","volume":"14","author":"Y Chen","year":"2023","unstructured":"Chen Y, Fang H, Sun H, Wu X, Xu Y, Zhou BBS (2023) Up-regulation of ABCG1 is associated with methotrexate resistance in acute lymphoblastic leukemia cells. Front Pharmacol 14:1331687","journal-title":"Front Pharmacol"},{"key":"12659_CR46","doi-asserted-by":"publisher","first-page":"43733","DOI":"10.18632\/oncotarget.16376","volume":"8","author":"K Ando","year":"2017","unstructured":"Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM (2017) Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Oncotarget 8:43733","journal-title":"Oncotarget"},{"key":"12659_CR47","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1021\/acs.jproteome.4c00885","volume":"24","author":"A Mukherjee","year":"2025","unstructured":"Mukherjee A, Manna S, Singh A, Ray A, Srivastava S (2025) Investigating cisplatin resistance in squamous cervical cancer: proteomic insights into DNA repair pathways and omics-based drug repurposing. J Proteome Res 24:2628","journal-title":"J Proteome Res"},{"key":"12659_CR48","doi-asserted-by":"publisher","first-page":"eabn2707","DOI":"10.1126\/scisignal.abn2707","volume":"15","author":"AM Kurimchak","year":"2022","unstructured":"Kurimchak AM, Herrera-Mont\u00e1vez C, Montserrat-Sangr\u00e0 S, Araiza-Olivera D, Hu J, Neumann-Domer R (2022) The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Sci Signal 15:eabn2707","journal-title":"Sci Signal"},{"key":"12659_CR49","doi-asserted-by":"publisher","first-page":"738e9","DOI":"10.1016\/j.urolonc.2020.05.008","volume":"38","author":"J Salimian","year":"2020","unstructured":"Salimian J, Baradaran B, Azimzadeh Jamalkandi S, Moridikia A, Ahmadi A (2020) MiR-486-5p enhances cisplatin sensitivity of human muscle-invasive bladder cancer cells by induction of apoptosis and down-regulation of metastatic genes. Urol Oncol 38:738e9","journal-title":"Urol Oncol"},{"key":"12659_CR50","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2023","unstructured":"Lei ZN, Tian Q, Teng QX, Wurpel JND, Zeng L, Pan Y, Chen ZS (2023) Understanding and targeting resistance mechanisms in cancer. MedComm 4:e265","journal-title":"MedComm"},{"key":"12659_CR51","doi-asserted-by":"publisher","first-page":"8259470","DOI":"10.1155\/sci5\/8259470","volume":"2025","author":"M Kakkadath","year":"2025","unstructured":"Kakkadath M, Naidu D, Kanthlal SK, Sharun K (2025) Combating methotrexate resistance in cancer treatment: a review on navigating pathways and enhancing its efficacy with fat-soluble vitamins. Scientifica 2025:8259470","journal-title":"Scientifica"},{"key":"12659_CR52","doi-asserted-by":"publisher","first-page":"648491","DOI":"10.3389\/fphar.2021.648491","volume":"12","author":"J Lu","year":"2021","unstructured":"Lu J, Zhao H, Yu C, Kang Y, Yang X (2021) Targeting ubiquitin-specific protease 7 (USP7) in cancer: a new insight to overcome drug resistance. Front Pharmacol 12:648491","journal-title":"Front Pharmacol"},{"issue":"15","key":"12659_CR53","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1128\/MCB.01062-15","volume":"36","author":"S Grieve","year":"2016","unstructured":"Grieve S, Gao Y, Hall C, Hu J, Greer PA (2016) Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis. Mol Cell Biol 36(15):2078\u20132088. https:\/\/doi.org\/10.1128\/MCB.01062-15 PMID: 27215381; PMCID: PMC4946432","journal-title":"Mol Cell Biol"},{"key":"12659_CR54","first-page":"30","volume":"21","author":"T Fujimoto","year":"2021","unstructured":"Fujimoto T, Tsunedomi R, Matsukuma S, Yoshimura K, Oga A, Fujiwara N, Fujiwara Y, Matsui H, Shindo Y, Tokumitsu Y, Suzuki N, Kobayashi S, Hazama S, Eguchi H, Nagano H (2021) Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients\u2019 surgical outcomes. Oncol Lett 21:30","journal-title":"Oncol Lett"},{"key":"12659_CR55","doi-asserted-by":"crossref","unstructured":"Qiong L, Yin J (2021) Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9, vol 12. Bioengineered, p 8822","DOI":"10.1080\/21655979.2021.1987067"},{"key":"12659_CR56","first-page":"27","volume-title":"Mitochondrial proteases in cancer development and progression. Pathophysiological Aspects of Proteases in Cancer","author":"GA Kurian","year":"2024","unstructured":"Kurian GA, Sivakumar B (2024) Mitochondrial proteases in cancer development and progression. Pathophysiological Aspects of Proteases in Cancer. Academic, London, pp 27\u201344"},{"key":"12659_CR57","doi-asserted-by":"publisher","first-page":"109769","DOI":"10.1016\/j.cbi.2021.109769","volume":"351","author":"B Sivakumar","year":"2022","unstructured":"Sivakumar B, Kurian GA (2022) Diesel particulate matter exposure deteriorates cardiovascular health and increases the sensitivity of rat heart towards ischemia reperfusion injury via suppressing mitochondrial bioenergetics function. Chem Biol Interact 351:109769 Published online 2021 Dec 4. https:\/\/doi.org\/10.1016\/j.cbi.2021.109769","journal-title":"Chem Biol Interact"},{"key":"12659_CR58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1369\/00221554211035192","volume":"69","author":"A Habi\u010d","year":"2021","unstructured":"Habi\u010d A, Novak M, Majc B, Lah Turn\u0161ek T, Breznik B (2021) Proteases regulate cancer stem cell properties and remodel their microenvironment. J Histochem Cytochem 69:775","journal-title":"J Histochem Cytochem"},{"key":"12659_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/cancers17020228","volume":"17","author":"E B\u0142aszczak","year":"2025","unstructured":"B\u0142aszczak E, Miziak P, Odrzywolski A, Baran M, Gumbarewicz E, Stepulak A (2025) Triple-negative breast cancer progression and drug resistance in the context of epithelial\u2013mesenchymal transition. Cancers 17:2","journal-title":"Cancers"},{"key":"12659_CR60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41419-025-07449-8","volume":"16","author":"M Yao","year":"2025","unstructured":"Yao M, Zhang X, Wu T, Feng T, Bian X, Abudurexiti M, Wang W, Shi G, Wei GH, Zhang Q, Li X, Feng G, Du L, Wang J (2025) Lon protease 1-mediated metabolic reprogramming promotes the progression of prostate cancer. Cell Death Dis 16:116","journal-title":"Cell Death Dis"},{"key":"12659_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-019-0054-9","volume":"4","author":"Y Lyu","year":"2019","unstructured":"Lyu Y, Xiao Q, Yin L, Yang L, He W (2019) Potent delivery of an MMP inhibitor to the tumor microenvironment with thermosensitive liposomes for the suppression of metastasis and angiogenesis. Signal Transduct Target Ther 4:26","journal-title":"Signal Transduct Target Ther"},{"key":"12659_CR62","doi-asserted-by":"publisher","first-page":"9748","DOI":"10.1021\/acsomega.2c08279","volume":"8","author":"A Dakshinamoorthy","year":"2023","unstructured":"Dakshinamoorthy A, Asmita A, Senapati S (2023) Comprehending the structure, dynamics, and mechanism of action of drug-resistant HIV protease. ACS Omega 8:9748","journal-title":"ACS Omega"},{"key":"12659_CR63","doi-asserted-by":"publisher","first-page":"850","DOI":"10.2174\/1573409916666201006143007","volume":"17","author":"MA Khan","year":"2021","unstructured":"Khan MA, Gupta KK, Singh SK (2021) A review on pharmacokinetics properties of antiretroviral drugs to treat HIV-1 infections. Curr Comput Aided Drug Des 17:850","journal-title":"Curr Comput Aided Drug Des"},{"key":"12659_CR64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks P, Coker EA, Vis DJ, Edwards O, Carpenter EF, Leto SM, Dwane L, Sassi F, Lightfoot H, Barthorpe S, van der Meer D, Yang W, Beck A, Mironenko T, Hall C, Hall J, Mali I, Richardson L, Tolley C, Morris J, Thomas F, Lleshi E, Aben N, Benes CH, Bertotti A, Trusolino L, Wessels L, Garnett MJ (2022) Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603:166","journal-title":"Nature"},{"issue":"16","key":"12659_CR65","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2007.15.8862","volume":"26","author":"TB Brunner","year":"2008","unstructured":"Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A et al (2008) Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 26(16):2699\u20132706. https:\/\/doi.org\/10.1200\/JCO.2007.15.8862","journal-title":"J Clin Oncol"},{"issue":"2","key":"12659_CR66","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.008","volume":"119","author":"JM Wilson","year":"2016","unstructured":"Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu KY, Durrant L, Abraham AG, Partridge M, Woodward M, O\u2019Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB (2016) ARCII: A phase II trial of the HIV protease inhibitor nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol 119(2):306\u2013311. https:\/\/doi.org\/10.1016\/j.radonc.2016.03.008","journal-title":"Radiother Oncol"},{"key":"12659_CR67","doi-asserted-by":"publisher","first-page":"114236","DOI":"10.1016\/j.ejca.2024.114236","volume":"209","author":"S Mukherjee","year":"2024","unstructured":"Mukherjee S, Qi C, Shaw R, Jones CM, Bridgewater JA, Radhakrishna G, Patel N et al (2024) Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1\/randomised phase 2 SCALOP-2 trial. Eur J Cancer 209:114236. https:\/\/doi.org\/10.1016\/j.ejca.2024.114236","journal-title":"Eur J Cancer"},{"issue":"1","key":"12659_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ (2016) ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7","journal-title":"Lancet Oncol"},{"key":"12659_CR69","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1158\/2767-9764.CRC-24-0102","volume":"4","author":"C Sgadari","year":"2024","unstructured":"Sgadari C, Scoppio B, Picconi O, Tripiciano A, Gaiani FM, Francavilla V (2024) Clinical efficacy of the HIV protease inhibitor indinavir in combination with chemotherapy for advanced classic Kaposi sarcoma treatment: a single-arm, phase II trial in the elderly. Cancer Res Commun 4:2112","journal-title":"Cancer Res Commun"},{"key":"12659_CR70","doi-asserted-by":"publisher","first-page":"875208","DOI":"10.3389\/fmolb.2022.875208","volume":"9","author":"L Makgoo","year":"2022","unstructured":"Makgoo L, Mosebi S, Mbita Z (2022) Molecular mechanisms of HIV protease inhibitors against HPV-associated cervical cancer: restoration of TP53 tumour suppressor activities. Front Mol Biosci 9:875208","journal-title":"Front Mol Biosci"},{"key":"12659_CR71","first-page":"101987","volume":"42","author":"R Reddy","year":"2025","unstructured":"Reddy R, Gaiwak V, Goda JS, Teni T (2025) Nelfinavir sensitizes a clinically relevant chemo-radioresistant cervical cancer in-vitro model by targeting the AKT-USP15\/USP11-HPV16 E6\/E7 axis. Biochem Biophys Rep 42:101987","journal-title":"Biochem Biophys Rep"},{"key":"12659_CR72","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.3390\/ijms21249739","volume":"21","author":"GA Cabral-Pacheco","year":"2020","unstructured":"Cabral-Pacheco GA, Garza-Veloz I, De la Rosa CC, Ramirez-Acu\u00f1a JM, Perez-Romero BA, Guerrero-Rodriguez JF (2020) The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci 21:9739","journal-title":"Int J Mol Sci"},{"issue":"3","key":"12659_CR73","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11060-005-9098-5","volume":"78","author":"VA Levin","year":"2006","unstructured":"Levin VA, Phuphanich S, Yung WK et al (2006) Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 78(3):295\u2013302. https:\/\/doi.org\/10.1007\/s11060-005-9098-5","journal-title":"J Neurooncol"},{"key":"12659_CR74","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.3390\/molecules28145567","volume":"28","author":"S Almutairi","year":"2023","unstructured":"Almutairi S, Kalloush HM, Manoon NA, Bardaweel SK (2023) Matrix metalloproteinases inhibitors in cancer treatment: an updated review (2013\u20132023). Molecules 28:5567","journal-title":"Molecules"},{"key":"12659_CR75","doi-asserted-by":"publisher","first-page":"1517519","DOI":"10.3389\/fimmu.2025.1517519","volume":"16","author":"J Liu","year":"2025","unstructured":"Liu J, Li Y, Lian X, Zhang C, Feng J, Tao H, Wang Z (2025) Potential target within the tumor microenvironment - MT1-MMP. Front Immunol 16:1517519","journal-title":"Front Immunol"},{"key":"12659_CR76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ph14010031","volume":"14","author":"N Das","year":"2020","unstructured":"Das N, Benko C, Gill SE, Dufour A (2020) The pharmacological TAILS of matrix metalloproteinases and their inhibitors. Pharmaceuticals 14:31","journal-title":"Pharmaceuticals"},{"key":"12659_CR77","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3390\/biom12050604","volume":"12","author":"PV da Silva-Neto","year":"2022","unstructured":"da Silva-Neto PV, do Valle VB, Fuzo CA et al (2022) Matrix metalloproteinases on severe COVID-19 lung disease pathogenesis: cooperative actions of MMP-8\/MMP-2 axis on immune response through HLA-G shedding and oxidative stress. Biomolecules 12:604","journal-title":"Biomolecules"},{"key":"12659_CR78","doi-asserted-by":"publisher","first-page":"e055765","DOI":"10.1136\/bmjopen-2021-055765","volume":"12","author":"S Chopra","year":"2022","unstructured":"Chopra S, Goda JS, Mittal P, Mulani J, Pant S, Pai V, Kannan S, Deodhar K, Krishnamurthy MN, Menon S, Charnalia M, Shah S, Rangarajan V, Gota V, Naidu L, Sawant S, Thakkar P, Popat P, Ghosh J, Rath S, Gulia S, Engineer R, Mahantshetty U, Gupta S (2022) Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial. BMJ Open 12:e055765","journal-title":"BMJ Open"},{"key":"12659_CR79","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jfma.2020.10.034","volume":"120","author":"YJ Chiu","year":"2021","unstructured":"Chiu YJ, Chen SC, Kang YN, Hou SK, Chao CC, Chang CC (2021) Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized clinical trials. J Formos Med Assoc 120:1090","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"12659_CR80","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.biochi.2010.04.023","volume":"92","author":"BT Elie","year":"2010","unstructured":"Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA (2010) Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie 92(11):1618\u20131624. https:\/\/doi.org\/10.1016\/j.biochi.2010.04.023","journal-title":"Biochimie"},{"issue":"18","key":"12659_CR81","first-page":"5230","volume":"62","author":"F Pajonk","year":"2002","unstructured":"Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH (2002) The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62(18):5230\u20135235","journal-title":"Cancer Res"},{"issue":"1","key":"12659_CR82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2013.08.045","volume":"342","author":"R Kariya","year":"2014","unstructured":"Kariya R, Taura M, Suzu S, Kai H, Katano H, Okada S (2014) HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-\u03baB pathway. Cancer Lett 342(1):52\u201359. https:\/\/doi.org\/10.1016\/j.canlet.2013.08.045","journal-title":"Cancer Lett"},{"issue":"18 Pt 1","key":"12659_CR83","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.1158\/1078-0432.CCR-04-0422","volume":"10","author":"MH Shah","year":"2004","unstructured":"Shah MH, Young D, Kindler HL et al (2004) Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10(18 Pt 1):6111\u20136118. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0422","journal-title":"Clin Cancer Res"},{"issue":"5","key":"12659_CR84","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2217\/fon.11.42","volume":"7","author":"ML Khan","year":"2011","unstructured":"Khan ML, Stewart AK (2011) Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol 7(5):607\u2013612. https:\/\/doi.org\/10.2217\/fon.11.42","journal-title":"Future Oncol"},{"issue":"4","key":"12659_CR85","first-page":"401","volume":"8","author":"KG Ramirez","year":"2017","unstructured":"Ramirez KG (2017) Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma. J Adv Pract Oncol 8(4):401\u2013405","journal-title":"J Adv Pract Oncol"},{"issue":"4","key":"12659_CR86","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/JTO.0b013e31820c9e3c","volume":"6","author":"A Srirangam","year":"2011","unstructured":"Srirangam A, Milani M, Mitra R et al (2011) The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin. J Thorac Oncol 6(4):661\u2013670. https:\/\/doi.org\/10.1097\/JTO.0b013e31820c9e3c","journal-title":"J Thorac Oncol"},{"issue":"22","key":"12659_CR87","doi-asserted-by":"publisher","first-page":"10920","DOI":"10.1158\/0008-5472.CAN-07-0796","volume":"67","author":"P Pyrko","year":"2007","unstructured":"Pyrko P, Kardosh A, Wang W, Xiong W, Sch\u00f6nthal AH, Chen TC (2007) HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 67(22):10920\u201310928. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0796","journal-title":"Cancer Res"},{"issue":"2","key":"12659_CR88","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3851\/IMP1512","volume":"15","author":"M Israr","year":"2010","unstructured":"Israr M, Mitchell D, Alam S, Dinello D, Kishel JJ, Meyers C (2010) Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium. Antivir Ther 15(2):253\u2013265. https:\/\/doi.org\/10.3851\/IMP1512","journal-title":"Antivir Ther"},{"issue":"9","key":"12659_CR89","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ecco-jcc\/jjy070","volume":"12","author":"S Schreiber","year":"2018","unstructured":"Schreiber S, Siegel CA, Friedenberg KA et al (2018) A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn\u2019s Disease. J Crohns Colitis 12(9):1014\u20131020. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy070","journal-title":"J Crohns Colitis"},{"issue":"12","key":"12659_CR90","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/ph13120421","volume":"13","author":"A Gitlin-Domagalska","year":"2020","unstructured":"Gitlin-Domagalska A, Maciejewska A, D\u0119bowski D (2020) Bowman-Birk Inhibitors: Insights into Family of Multifunctional Proteins and Peptides with Potential Therapeutical Applications. Pharmaceuticals (Basel) 13(12):421 Published 2020 Nov 25. https:\/\/doi.org\/10.3390\/ph13120421","journal-title":"Pharmaceuticals (Basel)"},{"key":"12659_CR91","doi-asserted-by":"publisher","first-page":"64592","DOI":"10.1021\/acsami.4c15342","volume":"16","author":"D Yun","year":"2024","unstructured":"Yun D, Fagan E, Shin D, Back W, Lee S, Kim MS, Park H, Park JH, Kim YC (2024) pH and redox dual-responsive nanoparticle with enhanced dendritic cell maturation for cancer therapy. ACS Appl Mater Interfaces 16:64592","journal-title":"ACS Appl Mater Interfaces"},{"key":"12659_CR92","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/cas.16443","volume":"116","author":"M Yamazaki","year":"2025","unstructured":"Yamazaki M, Ishimoto T (2025) Targeting cancer-associated fibroblasts: eliminate or reprogram? Cancer Sci 116:613","journal-title":"Cancer Sci"},{"key":"12659_CR93","first-page":"7290","volume":"24","author":"GT Kennedy","year":"2022","unstructured":"Kennedy GT, Azari FS, Nadeem B, Chang A, Segil A, Bernstein E, Desphande C, Kucharczuk JC, Delikatny EJ, Singhal S (2022) Preclinical evaluation of an activity-based probe for intraoperative imaging of esophageal cancer. Mol Imaging Biol 24:7290","journal-title":"Mol Imaging Biol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12659-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12659-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12659-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:03:41Z","timestamp":1788865421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12659-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12659"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12659-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human or animal experiments were directly conducted in this review article.","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1548"}}